Southside Bancshares, Inc. (SBSI) Touches $34.96 Formed H&S; 14 Analysts Bullish Hologic, Inc. (HOLX)

Southside Bancshares, Inc. (SBSI) formed inverse H&S with $36.36 target or 4.00% above today’s $34.96 share price. Southside Bancshares, Inc. (SBSI) has $1.22B valuation. The stock decreased 0.48% or $0.17 during the last trading session, reaching $34.96. About 74,734 shares traded. Southside Bancshares, Inc. (NASDAQ:SBSI) has risen 21.44% since January 25, 2017 and is uptrending. It has outperformed by 4.74% the S&P500.

Among 17 analysts covering Hologic (NASDAQ:HOLX), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Hologic had 49 analyst reports since July 24, 2015 according to SRatingsIntel. Barclays Capital upgraded Hologic, Inc. (NASDAQ:HOLX) on Friday, September 23 to “Overweight” rating. The rating was upgraded by Cowen & Co on Wednesday, December 20 to “Buy”. The firm earned “Buy” rating on Wednesday, January 3 by Canaccord Genuity. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Buy” rating given on Friday, June 2 by Needham. As per Thursday, August 3, the company rating was maintained by Canaccord Genuity. Stifel Nicolaus upgraded the shares of HOLX in report on Friday, December 11 to “Buy” rating. The firm has “Buy” rating given on Monday, August 3 by Argus Research. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Hold” rating given on Thursday, April 28 by Needham. Deutsche Bank downgraded Hologic, Inc. (NASDAQ:HOLX) rating on Friday, January 19. Deutsche Bank has “Hold” rating and $46.0 target. The firm earned “Overweight” rating on Wednesday, January 4 by PiperJaffray. See Hologic, Inc. (NASDAQ:HOLX) latest ratings:

19/01/2018 Broker: Deutsche Bank Rating: Hold New Target: $46.0 Downgrade
09/01/2018 Broker: Needham Rating: Buy New Target: $50.0 Maintain
08/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $51.0 Maintain
04/01/2018 Broker: Bank of America Rating: Buy New Target: $50.0 Upgrade
03/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $50.0 Maintain
03/01/2018 Broker: Evercore Rating: Outperform New Target: $50 Initiates Coverage On
21/12/2017 Broker: Jefferies Rating: Buy New Target: $52.0 Maintain
20/12/2017 Broker: Cowen & Co Rating: Buy New Target: $52.0 Upgrade
11/12/2017 Broker: Cowen & Co Old Rating: Market Perform New Rating: Outperform Upgrade
09/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $45.0

Analysts await Southside Bancshares, Inc. (NASDAQ:SBSI) to report earnings on January, 26. They expect $0.50 EPS, up 19.05% or $0.08 from last year’s $0.42 per share. SBSI’s profit will be $17.48 million for 17.48 P/E if the $0.50 EPS becomes a reality. After $0.49 actual EPS reported by Southside Bancshares, Inc. for the previous quarter, Wall Street now forecasts 2.04% EPS growth.

Among 5 analysts covering Southside Bancshares (NASDAQ:SBSI), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Southside Bancshares has $3800 highest and $28 lowest target. $34’s average target is -2.75% below currents $34.96 stock price. Southside Bancshares had 9 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, June 1 by Keefe Bruyette & Woods. As per Tuesday, October 3, the company rating was maintained by Keefe Bruyette & Woods. Piper Jaffray initiated it with “Hold” rating and $37.0 target in Friday, September 22 report. The rating was maintained by Piper Jaffray on Friday, October 27 with “Hold”. The rating was maintained by Keefe Bruyette & Woods on Thursday, December 21 with “Hold”. As per Monday, August 28, the company rating was maintained by Keefe Bruyette & Woods.

Investors sentiment decreased to 1.63 in 2017 Q3. Its down 0.45, from 2.08 in 2017Q2. It turned negative, as 7 investors sold Southside Bancshares, Inc. shares while 28 reduced holdings. 7 funds opened positions while 50 raised stakes. 14.40 million shares or 0.51% less from 14.48 million shares in 2017Q2 were reported. 23,832 are owned by State Of Tennessee Treasury Department. Prudential Fincl has 46,394 shares. Citadel Advisors Limited Com has invested 0% in Southside Bancshares, Inc. (NASDAQ:SBSI). Alliancebernstein Ltd Partnership invested 0% of its portfolio in Southside Bancshares, Inc. (NASDAQ:SBSI). Jpmorgan Chase invested 0% in Southside Bancshares, Inc. (NASDAQ:SBSI). 768 are held by Fifth Third State Bank. Bbva Compass Fincl Bank Inc holds 0.01% or 5,619 shares in its portfolio. Vanguard Gp invested in 1.79 million shares or 0% of the stock. Walthausen Limited holds 348,417 shares or 1.18% of its portfolio. Pitcairn Com has 5,822 shares. 42,561 are held by First Trust Lp. State Of Alaska Department Of Revenue owns 5,378 shares or 0.01% of their US portfolio. Tower Research Capital Limited Liability Corporation (Trc) has 2,994 shares. Envestnet Asset Mngmt Incorporated has 13,928 shares for 0% of their portfolio. Sei Investments Co holds 0% in Southside Bancshares, Inc. (NASDAQ:SBSI) or 22,768 shares.

Since August 7, 2017, it had 1 insider buy, and 3 selling transactions for $278,094 activity. Boyd Peter M sold $26,394 worth of stock. 1,500 shares valued at $49,500 were sold by MCCABE BRIAN K on Thursday, September 14. Another trade for 1,000 shares valued at $35,450 was bought by MORGAN TONY K. 7,000 shares valued at $237,650 were sold by Carter Tim on Monday, August 7.

The stock decreased 0.12% or $0.05 during the last trading session, reaching $42.9. About 2.63 million shares traded. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since January 25, 2017 and is uptrending. It has outperformed by 12.51% the S&P500.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company has market cap of $11.83 billion. It operates through four divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It has a 16.25 P/E ratio. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test.